Metformin before and during pregnancy and lactation in polycystic ovary syndrome

Bibliography

• KNOCHENHAUER ES, KEY TJ, KAHSAR-MILLER M, WAGGONER W, BOOTS LR, AZZIZ R: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin. Endocrinol. Metab. (1998) 83:3078-3082.
   PubMed Web of Science ®Google Scholar
• FRANKS S: Polycystic ovary syndrome. N. Engl. J. Med. (1995) 333:853-861.
   PubMed Web of Science ®Google Scholar
• ROTTERDAM ESHRE/ASRM-SPONSORED PCOS CONSENSUS WORKSHOP GROUP: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. (2004) 81:19-25.
   Web of Science ®Google Scholar
• EHRMANN DA: Polycystic ovary syndrome. N. Engl. J. Med. (2005) 352:1223-1236.
   PubMed Web of Science ®Google Scholar
• EHRMANN DA, STURIS J, BYRNE MM, KARRISON T, ROSENFIELD RL, POLONSKY KS: Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J. Clin. Invest. (1995) 96:520-527.
   PubMed Web of Science ®Google Scholar
• VELAZQUEZ EM, MENDOZA S, HAMER T, SOSA F, GLUECK CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism (1994) 43:647-654.
   PubMed Web of Science ®Google Scholar
• VELAZQUEZ EM, MENDOZA SG, WANG P, GLUECK CJ: Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism (1997) 46:454-457.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, WANG P, FONTAINE R, TRACY T, SIEVE-SMITH L: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism (1999) 48:511-519.
   PubMed Web of Science ®Google Scholar
• HARBORNE LR, SATTAR N, NORMAN JE, FLEMING R: Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J. Clin. Endocrinol. Metab. (2005) 90:4593-4598.
   PubMed Web of Science ®Google Scholar
• BAILLARGEON JP, JAKUBOWICZ DJ, IUOMO MJ, JAKUBOWICZ S, NESTLER JE: Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Obstet. Gynecol. Surv. (2005) 60:178-179.
   Google Scholar
• HOMBURG R: Polycystic ovary syndrome in adolescence. New insights in pathophysiology and treatment. Endocr. Dev. (2005) 8:137-149.
   PubMedGoogle Scholar
• KUMARI AS, HAQ A, JAYASUNDARAM R, ABDEL-WARETH LO, AL HAIJA SA, ALVARES M: Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod. Biomed. Online (2005) 10:100-104.
   PubMed Web of Science ®Google Scholar
• PALOMBA S, ORIO F Jr, FALBO A et al.: Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2005) 90:4068-4074.
   PubMed Web of Science ®Google Scholar
• NESTLER JE, JAKUBOWICZ DJ, EVANS WS, PASQUALI R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med. (1998) 338:1876-1880.
   PubMed Web of Science ®Google Scholar
• LIU JH, BILL AH: Expanding applications for metformin in polycystic ovarian syndrome. J. Pediatr. (2006) 148:573-574.
   PubMed Web of Science ®Google Scholar
• CHECA MA, REQUENA A, SALVADOR C et al.: Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum. Reprod. Update (2005) 11:375-390.
   PubMed Web of Science ®Google Scholar
• GARDINER SJ, BEGG EJ, KIRKPATRICK CM, BUCKHAM RB: Metformin therapy and diabetes in pregnancy. Med. J. Aust. (2004) 181:174-175.
   PubMedGoogle Scholar
• GILBERT C, VALOIS M, KOREN G: Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil. Steril. (2006) 86:658-663.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, PHILLIPS H, CAMERON D, SIEVE-SMITH L, WANG P: Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil. Steril. (2001) 75:46-52.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, WANG P, KOBAYASHI S, PHILLIPS H, SIEVE-SMITH L: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil. Steril. (2002) 77:520-525.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, WANG P, GOLDENBERG N, SIEVE-SMITH L: Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum. Reprod. (2002) 17:2858-2864.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, BORNOVALI S, PRANIKOFF J, GOLDENBERG N, DHARASHIVKAR S, WANG P: Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet. Med. (2004) 21:829-836.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, GOLDENBERG N, WANG P, LOFTSPRING M, SHERMAN A: Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum. Reprod. (2004) 19:510-521.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, SALEHI M, SIEVE L, WANG P: Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. J. Pediatr. (2006) 148:628-632.
   PubMed Web of Science ®Google Scholar
• COETZEE EJ, JACKSON WP: Diabetes newly diagnosed during pregnancy: a 4-year study at Groote Schuur Hospital. S. Afr. Med. J. (1979) 56:467-475.
   PubMed Web of Science ®Google Scholar
• COETZEE EJ, JACKSON WP: Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Groote Schuur Hospital. S. Afr. Med. J. (1980) 58:795-802.
   PubMed Web of Science ®Google Scholar
• LEGRO RS, MYERS ER, BARNHART HX et al.: The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil. Steril. (2006) 86:914-933.
   PubMed Web of Science ®Google Scholar
• THATCHER SS, JACKSON EM: Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil. Steril. (2006) 85:1002-1009.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, SIEVE L, ZHU B, WANG P: Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism (2006) 55:345-352.
   PubMed Web of Science ®Google Scholar
• KHATTAB S, MOHSEN IA, FOUTOUH IA, RAMADAN A, MOAZ M, AL-INANY H: Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol. Endocrinol. (2006) 22:680-684.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, GOLDENBERG N, STREICHER P, WANG P: The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin. Pharmacother. (2002) 3:1557-1568.
   PubMedGoogle Scholar
• GLUECK CJ, GOLDENBERG N, STREICHER P, WANG P: Metformin and gestational diabetes. Curr. Diab. Rep. (2003) 3:303-312.
   PubMedGoogle Scholar
• GLUECK CJ, WANG P, GOLDENBERG N, SIEVE L: Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin. Appl. Thromb. Hemost. (2004) 10:323-334.
   PubMed Web of Science ®Google Scholar
• JAKUBOWICZ DJ, IUORNO MJ, JAKUBOWICZ S, ROBERTS KA, NESTLER JE: Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2002) 87:524-529.
   PubMed Web of Science ®Google Scholar
• VANKY E, SALVESEN KA, HEIMSTAD R, FOUGNER KJ, ROMUNDSTAD P, CARLSEN SM: Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum. Reprod. (2004) 19:1734-1740.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, GOLDENBERG N, PRANIKOFF J, LOFTSPRING M, SIEVE L, WANG P: Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum. Reprod. (2004) 19:1323-1330.
   PubMed Web of Science ®Google Scholar
• HAGUE WM DP, OLIVER J, ROWAN J: Contraindications to use of metformin. Metformin may be useful in gestational diabetes. Br. Med. J. (2003) 326:762.
   PubMedGoogle Scholar
• BAILLARGEON JP, IUORNO MJ, NESTLER JE: Insulin sensitizers for polycystic ovary syndrome. Clin. Obstet. Gynecol. (2003) 46:325-340.
   PubMed Web of Science ®Google Scholar
• HALE TW, KRISTENSEN JH, HACKETT LP, KOHAN R, ILETT KF: Transfer of metformin into human milk. Diabetologia (2002) 45:1509-1514.
   PubMed Web of Science ®Google Scholar
• BRIGGS GG, AMBROSE PJ, NAGEOTTE MP, PADILLA G, WAN S: Excretion of metformin into breast milk and the effect on nursing infants. Obstet. Gynecol. (2005) 105:1437-1441.
   PubMed Web of Science ®Google Scholar
• GARDINER SJ, KIRKPATRICK CM, BEGG EJ, ZHANG M, MOORE MP, SAVILLE DJ: Transfer of metformin into human milk. Clin. Pharmacol. Ther. (2003) 73:71-77.
   PubMed Web of Science ®Google Scholar
• DEROSA G, FRANZETTI I, GADALETA G, CICCARELLI L, FOGARI R: Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr. Metab. (2004) 17:143-150.
   PubMedGoogle Scholar
• MARASCO L, MARMET C, SHELL E: Polycystic ovary syndrome: a connection to insufficient milk supply? J. Hum. Lact. (2000) 16:143-148.
   PubMedGoogle Scholar
• PEDIATRICS AAO: Your child’s growth: developmental milestones. American Academy of Pediatrics Pamphlet (1993):1-3.
   Google Scholar
• HALE T, KRISTENSEN J, HACKETT L, KOHAN R, ILETT K: Transfer of metformin into human milk. Adv. Exp. Med. Biol. (2004) 554:435-436.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, PAPANNA R, WANG P, GOLDENBERG N, SIEVE-SMITH L: Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism (2003) 52:908-915.
   PubMed Web of Science ®Google Scholar
• VANKY E, SALVESEN KA, HJORTH-HANSEN H, BJERVE K, CARLSEN SM: Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation. Fertil. Steril. (2006) 85:770-774.
   PubMed Web of Science ®Google Scholar
• MIRRETT PL, BAILEY DB Jr, ROBERTS JE, HATTON DD: Developmental screening and detection of developmental delays in infants and toddlers with fragile X syndrome. J. Dev. Behav. Pediatr. (2004) 25:21-27.
   PubMed Web of Science ®Google Scholar
• NEIMAN GS, SAVAGE HE: Development of infants and toddlers with clefts from birth to three years of age. Cleft Palate Craniofac. J. (1997) 34:218-225.
   PubMed Web of Science ®Google Scholar
• WALKER D, GUGENHEIM S, DOWNS MP, NORTHERN JL: Early Language Milestone Scale and language screening of young children. Pediatrics (1989) 83:284-288.
   PubMed Web of Science ®Google Scholar
• BAILLARGEON JP, JAKUBOWICZ DJ, IUORNO MJ, JAKUBOWICZ S, NESTLER JE: Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil. Steril. (2004) 82:893-902.
   PubMed Web of Science ®Google Scholar
• DIAMANTI-KANDARAKIS E, ALEXANDRAKI K, PIPERI C et al.: Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur. J. Clin. Invest. (2006) 36:691-697.
   PubMed Web of Science ®Google Scholar
• ESSAH PA, NESTLER JE: Metabolic syndrome in women with polycystic ovary syndrome. Fertil. Steril. (2006) 86(Suppl. 1):S18-S19.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, AREGAWI D, WINIARSKA M et al.: Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J. Pediatr. Endocrinol. Metab. (2006) 19:831-842.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, MORRISON JA, FRIEDMAN LA, GOLDENBERG N, STROOP DM, WANG P: Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents. Metabolism (2006) 55:508-514.
   PubMed Web of Science ®Google Scholar
• ORTEGA-GONZALEZ C, LUNA S, HERNANDEZ L et al.: Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2005) 90:1360-1365.
   PubMed Web of Science ®Google Scholar
• BELLI SH, GRAFFIGNA MN, ONETO A, OTERO P, SCHURMAN L, LEVALLE OA: Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil. Steril. (2004) 81:624-629.
   PubMed Web of Science ®Google Scholar
• CATALDO NA, ABBASI F, MCLAUGHLIN TL et al.: Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum. Reprod. (2006) 21:109-120.
   PubMed Web of Science ®Google Scholar
• CHAN LY, LAU TK, FUNG TM, CHOW KM: Re: Effects of rosiglitazone on hormonal profile and ovulatory function in Chinese women with polycystic ovary syndrome. Aust. NZ. J. Obstet. Gynaecol. (2006) 46:170-171.
   PubMed Web of Science ®Google Scholar
• DERELI D, DERELI T, BAYRAKTAR F, OZGEN AG, YILMAZ C: Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr. J. (2005) 52:299-308.
   PubMed Web of Science ®Google Scholar
• GHAZEERI G, KUTTEH WH, BRYER-ASH M, HAAS D, KE RW: Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil. Steril. (2003) 79:562-566.
   PubMed Web of Science ®Google Scholar
• BRETTENTHALER N, DE GEYTER C, HUBER PR, KELLER U: Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (2004) 89:3835-3840.
   PubMed Web of Science ®Google Scholar
• ELKIND-HIRSCH KE: Thiazolidinediones for the therapeutic management of polycystic ovary syndrome: impact on metabolic and reproductive abnormalities. Treat. Endocrinol. (2006) 5:171-187.
   PubMedGoogle Scholar
• GARMES HM, TAMBASCIA MA, ZANTUT-WITTMANN DE: Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol. Endocrinol. (2005) 21:317-323.
   PubMed Web of Science ®Google Scholar
• YARIS F, YARIS E, KADIOGLU M, ULKU C, KESIM M, KALYONCU NI: Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod. Toxicol. (2004) 18:619-621.
   PubMed Web of Science ®Google Scholar
• KALYONCU NI, YARIS F, ULKU C et al.: A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod. Toxicol. (2005) 19:563-564.
   PubMed Web of Science ®Google Scholar
• SCIALLI AR, BUELKE-SAM JL, CHAMBERS CD et al.: Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res. A Clin. Mol. Teratol. (2004) 70:7-12.
   PubMed Web of Science ®Google Scholar
• KAUFMAN RH, ABBOTT JP, WALL JA: The endometrium before and after wedge resection of the ovaries in the Stein–Leventhal syndrome. Am. J. Obstet. Gynecol. (1959) 77:1271-1285.
   PubMed Web of Science ®Google Scholar